- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treating Hyperhidrosis: Glycopyrronium Tosylate
Shawn Davis, PharmD: Glycopyrronium tosylate is an exciting therapy that will enable patients to have something topical. This is something that I believe is going to help patients. It is really going to have an impact on their lives and change the way that they live their lives.
Glycopyrronium tosylate is a medication that is actually going to meet the needs of patients in a way that they don’t have today. There aren’t good therapies on the market for patients to treat their hyperhidrosis and the condition that they have.
The next part is going to really be seeing what managed care’s outlook will be in paying for these medications. We are going to have a therapy. Just like with all therapies that are on the market, how do we pay for it? What’s going to be the mechanism by which payers and patients split the cost?
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
